Related Experiment Video

Updated: Aug 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Statins in older patients: limits to prescription?]

W Bosshard Taroni1, C Büla, R Darioli

  • 1Service de gériatrie et réadaptation gériatrique CUTR Sylvana Epalinges.

Revue Medicale Suisse
|December 6, 2005
PubMed

Insights

Cardiovascular diseases are a leading cause of death in older adults. Treatment for high cholesterol in the elderly, especially for primary prevention in those over ninety, requires more specific data for informed decisions.

Area of Science:

  • Gerontology
  • Cardiology
  • Public Health

Context:

  • Cardiovascular diseases (CVD) significantly impact elderly mortality, morbidity, and functional decline.
  • Hypercholesterolemia is a critical risk factor in older populations.
  • Limited data specific to the elderly complicates treatment decisions for hypercholesterolemia.

Purpose:

  • To address the challenges in managing hypercholesterolemia in the elderly.
  • To evaluate the evidence for treating asymptomatic older individuals (primary prevention) versus those with existing CVD (secondary prevention).
  • To clarify treatment guidelines for very old patients (90s) with hypercholesterolemia.

Summary:

  • While treating elderly patients with existing cardiovascular disease (secondary prevention) up to their eighties is supported by evidence, the benefit of treating asymptomatic elderly individuals (primary prevention) remains less clear.
  • The decision-making process for hypercholesterolemia treatment in individuals aged 90 and above is particularly challenging due to insufficient population-specific data.
  • Further research is needed to establish optimal lipid management strategies for different elderly subgroups.

Impact:

  • Inform clinical practice guidelines for cardiovascular disease prevention in the elderly.
  • Improve risk stratification and treatment efficacy for hypercholesterolemia in older adults.
  • Enhance the quality of life and reduce healthcare burden associated with cardiovascular diseases in aging populations.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...